Bliss GVS Pharma Limited · BLISSGVS
Every Bliss GVS Pharma Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
25results judged
0read right
0read wrong
0flat / no call
25unread
36%beat the market
+1.5%avg vs market, 10d
5.2%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| unread | 25 | 0 | 0 | 0 | — | +1.5% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
25 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 12 Aug Q1FY27 | — | unread | +6.1% | +14.4% | +15.8% | -6% | no figures |
|
› |
| 12 May Q4FY26 | — | unread | +5.7% | +44.9% | +42.7% | — | no figures |
|
› |
| 10 Feb Q3FY26 | — | unread | +4.9% | +5.3% | +7.0% | +27% | no figures |
|
› |
| 6 Nov Q2FY26 | — | unread | -2.7% | +5.1% | +2.9% | +0% | no figures |
|
› |
| 29 Jul Q1FY26 | — | unread | +13.4% | +9.7% | +10.6% | +10% | no figures |
|
› |
| 12 May Q4FY25 | — | unread | +0.1% | +9.7% | +10.1% | -3% | no figures |
|
› |
| 29 Jan Q3FY25 | — | unread | +2.0% | -6.3% | -5.7% | -13% | no figures |
|
› |
| 25 Oct Q2FY25 | — | unread | +13.8% | +11.2% | +11.4% | -14% | no figures |
|
› |
| 25 Jul Q1FY25 | — | unread | +2.1% | -5.4% | -5.2% | +13% | no figures |
|
› |
| 3 May Q4FY24 | — | unread | -5.7% | -8.4% | -8.6% | +8% | no figures |
|
› |
| 24 Jan Q3FY24 | — | unread | -2.2% | +0.8% | -0.7% | -11% | no figures |
|
› |
| 2 Nov Q2FY24 | — | unread | — | +34.4% | +31.3% | +5% | no figures |
|
› |
| 1 Aug Q1FY24 | — | unread | -7.3% | -7.1% | -5.2% | +20% | no figures |
|
› |
| 12 May Q4FY23 | — | unread | -0.4% | -3.9% | -5.4% | +5% | no figures |
|
› |
| 25 Jan Q3FY23 | — | unread | +3.2% | -3.7% | -3.5% | +4% | no figures |
|
› |
| 9 Nov Q2FY23 | — | unread | -6.0% | -7.3% | -7.7% | -5% | no figures |
|
› |
| 4 Aug Q1FY23 | — | unread | +1.6% | -2.8% | -3.4% | +6% | no figures |
|
› |
| 30 Apr Q4FY22 | — | unread | -3.4% | -10.0% | -5.1% | +11% | no figures |
|
› |
| 30 Jan Q3FY22 | — | unread | -2.0% | -10.6% | -9.1% | -2% | no figures |
|
› |
| 30 Oct Q2FY22 | — | unread | -4.4% | -7.9% | -9.8% | -1% | no figures |
|
› |
| 31 Jul Q1FY22 | — | unread | +14.6% | +2.2% | -2.8% | -3% | no figures |
|
› |
| 13 May Q4FY21 | — | unread | -8.8% | -7.1% | -12.2% | +14% | no figures |
|
› |
| 22 Jan Q3FY21 | — | unread | -2.6% | -6.2% | -11.3% | +11% | no figures |
|
› |
| 22 Oct Q2FY21 | — | unread | +0.5% | -2.1% | -5.1% | +14% | no figures |
|
› |
| 21 Aug Q1FY21 | — | unread | +11.9% | +7.6% | +7.7% | +33% | no figures |
|
› |